Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Pharmacological approaches to cognitive enhancement have received considerable attention but have not had considerable success in improving their cognitive and functional targets. Other intervention strategies, such as cognitive remediation therapy (CRT), have been shown to enhance cognitive performance but have not been found to improve functional outcomes without additional psychosocial interventions. Recently, several studies have attempted to enhance the effects of CRT by adding pharmacological interventions to the CRT treatments. In addition, as CRT has been shown to synergistically improve the effects of psychosocial interventions, the combination of pharmacological therapies aimed at cognition and psychosocial interventions may itself provide a promising strategy for improving functional outcomes. This review and commentary examines the current state of interventions combining CRT and psychosocial treatments with pharmacological augmentation. Our focus is on the specific level of effect of the pharmacological intervention, which could be enhancing motivation, training efficiency, or the consolidation of therapeutic gains. Different pharmacological strategies (e.g., stimulants, plasticity-inducing agents, or attentional or alertness enhancers) may have the potential to lead to different types of gains when combined with CRT or psychosocial interventions. The relative potential of these different mechanisms for immediate and durable effects is considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 1×
“In particular, d-cycloserine (DCS), initially used to consolidate fear extinction gains (38), has been studied for its potential to modify the memory consolidation process (39).”
BackgroundDopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
Arnsten, A. F. T., Cai, J. X., Murphy, B. L., & Goldman-Rakic, P. S. (1994) · Psychopharmacology · doi:10.1007/bf02245056 · Cited by 566 · cited 1×
“Specifically, the D1 receptor agonist SKF 38393 was shown in several studies to have a direct beneficial effect on cognition in several animal models (71), although this compound does not cross the blood brain barrier in adequate concentrations to be useful for pharmacological augmentation.”
BackgroundSocial cognitive training for schizophrenia: a meta-analytic investigation of controlled research
Kurtz, M. M., & Richardson, C. L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr036 · Cited by 446
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 1×
“However, a longer study with more participants found no beneficial effects of treatment (68).”
BackgroundBuchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419 · cited 1×
“These results have been consistently negative when using DCS, cycloserine, glycine, and glycine transport inhibitors to improve cognition directly (41, 42).”
ResultArnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“Similar findings were reported for the noradrenergic alphaII agonist guanfacine, a currently approved treatment for attention deficit hyperactivity disorder found to improve cognition in animal models (76).”
ResultCognitive Training for Supported Employment: 2-3 Year Outcomes of a Randomized Controlled Trial
McGurk, S. R., Mueser, K. T., Feldman, Wolfe, & Pascaris (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.437 · Cited by 318
Bowie, C. R., McGurk, S. R., Mausbach, B., Patterson, T. L., & Harvey, P. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11091337 · Cited by 312 · cited 4×
“(20) used performance on a measure of functional capacity (the UPSA-B) as the index of treatment gains associated with a highly specific skills training program, vocational interventions are more challenging.”
BackgroundMethodSelf-citationCognition in Schizophrenia: Impairments, Determinants, and Functional Importance
Bowie, C. R., & Harvey, P. D. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.05.004 · Cited by 280
Self-citationPsychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation
Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. G. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007054 · Cited by 259
McGurk, S. R., Mueser, K. T., Xie, H., Welsh, J., Kaiser, S., Drake, R. E., Becker, D. R., Bailey, E., Fraser, G., Wolfe, R., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14030374 · Cited by 171
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
GOFF, D., CATHER, C., GOTTLIEB, J., EVINS, A., WALSH, J., RAEKE, L., OTTO, M., SCHOENFELD, D., & GREEN, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.012 · Cited by 144 · cited 1×
“In particular, d-cycloserine (DCS), initially used to consolidate fear extinction gains (38), has been studied for its potential to modify the memory consolidation process (39).”
BackgroundGuanfacine treatment of cognitive impairment in schizophrenia
Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113 · cited 1×
“In a clinical trial for schizophrenia, guanfacine did not improve cognition (77), but when used to treat patients with schizotypal personality disorder there was a significant positive treatment effect (78).”
BackgroundThe effects of guanfacine on context processing abnormalities in schizotypal personality disorder
McClure, M. M., Barch, D. M., Romero, M. J., Minzenberg, M. J., Triebwasser, J., Harvey, P. D., & Siever, L. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.034 · Cited by 70
Self-citationEnhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70 · cited 1×
“This area of investigation has been challenging because, as DCS causes memory consolidation, it can cause consolidation of both the extinction of the older memories and consolidation of memory recurrence as well (40).”
BackgroundDrake, R. J., Day, C. J., Picucci, R., Warburton, J., Larkin, W., Husain, N., Reeder, C., Wykes, T., & Marshall, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002559 · Cited by 58 · cited 1×
“Interestingly, there seems to be only one published study where CRT was combined with CBT in patients with severe mental illness (57).”
Background
Cited by
Nonsocial and social cognition in schizophrenia: current evidence and future directions
Green, M. F., Horan, W. P., & Lee, J. (2019) · World Psychiatry · doi:10.1002/wps.20624 · Cited by 612
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85
Vita, A., Barlati, S., Ceraso, A., Deste, G., Nibbio, G., & Wykes, T. (2023) · Psychological Medicine · doi:10.1017/s0033291722000319 · Cited by 74
“…on adherence to non-pharmacological interventions represents an interesting topic, also considering the growing literature interest for providing cognitive enhancement pharmacological strategies (Fleischhacker et al., 2021; Harvey & Sand, 2017; Michalopoulou et al., 2015; Otto et al., 2016).”
McClure, M. M., Graff, F., Triebwasser, J., Perez-Rodriguez, M., Rosell, D. R., Koenigsberg, H., Hazlett, E. A., Siever, L. J., Harvey, P. D., & New, A. S. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030349 · Cited by 38
“Additionally, although there have been several studies investigating the possible pharmacological facilitation of a cognitive remediation therapy regimen in individuals with schizophrenia [18], all pharmacological studies in schizotypal personality disorder have looked at medications alone.”
BackgroundSelf-citation
Metadata
- Authors
- Harvey, P. D., & Sand, M.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2017-09-25
- Volume
- 8
- Pages
- 177-177
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2758088217
- Cited by
- 29
- References
- 18
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.